Steroid News and Research

RSS

Vitamin D and progesterone combination for treating traumatic brain injury

As doctors begin to test progesterone for traumatic brain injury at sites across the country, researchers are looking ahead to optimizing the hormone's effectiveness.

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

Rituxan drug effective for treating ANCA-associated vasculitis

Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy.

19 Oct 2009

T.S. Wiley to lecture on the latest advances in anti-aging medicine

Wiley Systems™, Inc. announces that internationally acclaimed Author T.S. Wiley will be lecturing at the second annual European Congress on Anti-Aging & Aesthetic Medicine (ECAAAM) at the Congress Centre, Mainz, near Frankfurt, October 15-17, 2009. Wiley will give two lectures among other international experts presenting the latest advances in anti-aging medicine.

14 Oct 2009

Short, frequent bouts of lower intensity exercise can improve body image

Attention weekend warriors: the simple act of exercise and not fitness itself can convince you that you look better, a new University of Florida study finds.

9 Oct 2009

NEI awards Case Western Reserve $1.57M for bacterial keratitis research

Researchers at Case Western Reserve University School of Medicine have been awarded a $1.57 million renewal grant from the National Eye Institute (NEI) of the National Institutes of Health to continue their study of corneal infections, specifically, bacterial keratitis, associated with contact lens wear. The grant will extend the work initiated last year with the receipt of a $2.4 million, five-year grant from the NEI.

8 Oct 2009

Research must focus on discovering potential causes and treatments for Bell's palsy

Drugs widely prescribed to treat facial paralysis in Bell's palsy are ineffective and are based on false notions of the cause of the condition, according to Cochrane Researchers. They say research must now focus on discovering other potential causes and treatments.

7 Oct 2009

Survival rates for multivisceral transplants increase with new treatment strategies

Data from the largest single-center experience of adult and pediatric intestinal and multivisceral transplantation show that survival rates have improved with the advent of innovative surgical techniques, novel immunosuppressive protocols and better post-operative management, said researchers at the Thomas E. Starzl Transplantation Institute in a study published in the October issue of Annals of Surgery.

6 Oct 2009

New treatment for chronic sinusitis from Summit Ear, Nose & Throat

Summit Ear, Nose & Throat is the first in the area to offer an exciting new treatment for chronic sinusitis (CRS) in an outpatient setting called FinESS™ Sinus Treatment. FinESS is a new balloon sinuplasty technique that is less invasive than traditional sinus surgery and that breaks the cycle of chronic sinusitis with immediate relief and lasting results.

30 Sep 2009

Vitae receives 11Beta-HSD-1 program milestone payment from Boehringer Ingelheim

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned an $8 million milestone payment from Boehringer Ingelheim for achievement of a performance milestone in their 11beta-hydroxysteroid dehydrogenase (HSD)-1 diabetes and metabolic disease strategic alliance.

29 Sep 2009

pSivida reports interim results of human PK study of Iluvien

pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.

29 Sep 2009

Androgen deficiency linked to diabetes and cardiovascular diseases

Researchers from Boston University School of Medicine (BUSM) in collaboration with researchers from Lahey Clinic Northshore, Peabody, Mass., believe that androgen deficiency might be the underlying cause for a variety of common clinical conditions, including diabetes, erectile dysfunction, metabolic syndrome and cardiovascular disease (CVD). These findings appear in the September/October issue of the Journal of Andrology.

25 Sep 2009

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo’s oral, proprietary therapeutic for chronic autoimmune uveitis.

21 Sep 2009

Ipsen's Azzalure muscle relaxant receives Spanish AEMPS marketing approval

Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.

21 Sep 2009

Liver transplantation performed in a six-month old infant

Ila and her worried parents were referred to Lucile Packard Children's Hospital at Stanford, home of the busiest pediatric liver transplant team in the nation. The hospital's team performed more liver transplants in 2008 – the most recent reporting period – than any other U.S. children's hospital, according to the United Network for Organ Sharing. They also did the largest number of surgeries in infants like Ila, who were younger than one year when they received a transplant.

17 Sep 2009

Exercise is effective for treating chronic shoulder pain

Supervised exercises are more effective than shockwave treatment to relieve chronic shoulder pain, finds a study published on bmj.com today.

16 Sep 2009

Internet marketing program from AVVH

avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced today the launch of a major Internet marketing program.

14 Sep 2009

PTH therapy could prevent osteoarthritis

An existing osteoporosis drug is the first ever found to prevent cartilage loss from osteoarthritis following injury to a joint, and may also regenerate some cartilage that has been lost to osteoarthritis, according to an early study presented today at the annual meeting of the American Society for Bone and Mineral Research in Denver.

14 Sep 2009

Phase II clinical trial of TAK-700 for treating advanced prostate cancer commences

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer.

11 Sep 2009

Quatrx' second phase 3 study of ospemifene tablets provides positive results

QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA).

10 Sep 2009